FDA
-
-
-
-
-
-
-
IDEAYA begins FDA application for uveal melanoma drug under fast-track program
-
-
-
-
-
-
-
Ideaya Biosciences (IDYA) Reiterated at Market Outperform by Citizens: Shares Can Gain
-
-
-
-
-
-
-
IDEAYA Biosciences receives FDA clearance for cancer drug trial
-
-
-
-
-
-
-
IDEAYA reports phase 1/2 trial data for cancer drug combination
-
-
-
-
-
-
-
IDEAYA to present darovasertib trial data at ESMO 2025 conference
-
-
-
-
-
-
-
IDEAYA Biosciences (IDYA) Receives US FDA Breakthrough Therapy Designation for Darovasertib Monotherapy in Neoadjuvant Uveal Melanoma
-
-
-
-
-
-
-
IDEAYA Announces Development Candidate Nomination of IDE251, a Potential First-in-Class KAT6/7 Dual Inhibitor Targeting 8p11 Amplification Tumors in Breast and Lung Cancers
-
329,957 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

